CINXE.COM
Advancing Melanoma Treatment: The FDA Gives Lifileucel The Greenlight in Historic Cell & Gene Therapy Breakthrough
<!doctype html><html lang="en"><head> <meta charset="utf-8"> <title>Advancing Melanoma Treatment: The FDA Gives Lifileucel The Greenlight in Historic Cell & Gene Therapy Breakthrough</title> <link rel="shortcut icon" href="https://oxfordglobal.com/hubfs/OXFORD_GLOBAL-LOGO_SYMBOL.jpg"> <meta name="description" content="The Food and Drug Administration (FDA) approved Lifileucel, a one-of-a-kind T-cell therapy developed by Iovance Biotherapeutics for treating melanoma."> <meta name="viewport" content="width=device-width, initial-scale=1"> <meta property="og:description" content="The Food and Drug Administration (FDA) approved Lifileucel, a one-of-a-kind T-cell therapy developed by Iovance Biotherapeutics for treating melanoma."> <meta property="og:title" content="Advancing Melanoma Treatment: The FDA Gives Lifileucel The Greenlight in Historic Cell & Gene Therapy Breakthrough"> <meta name="twitter:description" content="The Food and Drug Administration (FDA) approved Lifileucel, a one-of-a-kind T-cell therapy developed by Iovance Biotherapeutics for treating melanoma."> <meta name="twitter:title" content="Advancing Melanoma Treatment: The FDA Gives Lifileucel The Greenlight in Historic Cell & Gene Therapy Breakthrough"> <style> a.cta_button{-moz-box-sizing:content-box !important;-webkit-box-sizing:content-box !important;box-sizing:content-box !important;vertical-align:middle}.hs-breadcrumb-menu{list-style-type:none;margin:0px 0px 0px 0px;padding:0px 0px 0px 0px}.hs-breadcrumb-menu-item{float:left;padding:10px 0px 10px 10px}.hs-breadcrumb-menu-divider:before{content:'›';padding-left:10px}.hs-featured-image-link{border:0}.hs-featured-image{float:right;margin:0 0 20px 20px;max-width:50%}@media (max-width: 568px){.hs-featured-image{float:none;margin:0;width:100%;max-width:100%}}.hs-screen-reader-text{clip:rect(1px, 1px, 1px, 1px);height:1px;overflow:hidden;position:absolute !important;width:1px} </style> <link rel="stylesheet" href="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/135726131582/1732113079147/git/og-stage/css/main.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/fontawesome.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/brands.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/solid.min.css"> <!-- Editor Styles --> <style id="hs_editor_style" type="text/css"> #hs_cos_wrapper_module_17019620504109 { display: block !important; margin-bottom: 0px !important } </style> <!-- Added by GoogleAnalytics4 integration --> <script> var _hsp = window._hsp = window._hsp || []; window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} var useGoogleConsentModeV2 = true; var waitForUpdateMillis = 1000; if (!window._hsGoogleConsentRunOnce) { window._hsGoogleConsentRunOnce = true; gtag('consent', 'default', { 'ad_storage': 'denied', 'analytics_storage': 'denied', 'ad_user_data': 'denied', 'ad_personalization': 'denied', 'wait_for_update': waitForUpdateMillis }); if (useGoogleConsentModeV2) { _hsp.push(['useGoogleConsentModeV2']) } else { _hsp.push(['addPrivacyConsentListener', function(consent){ var hasAnalyticsConsent = consent && (consent.allowed || (consent.categories && consent.categories.analytics)); var hasAdsConsent = consent && (consent.allowed || (consent.categories && consent.categories.advertisement)); gtag('consent', 'update', { 'ad_storage': hasAdsConsent ? 'granted' : 'denied', 'analytics_storage': hasAnalyticsConsent ? 'granted' : 'denied', 'ad_user_data': hasAdsConsent ? 'granted' : 'denied', 'ad_personalization': hasAdsConsent ? 'granted' : 'denied' }); }]); } } gtag('js', new Date()); gtag('set', 'developer_id.dZTQ1Zm', true); gtag('config', 'G-43QK8SYTST'); </script> <script async src="https://www.googletagmanager.com/gtag/js?id=G-43QK8SYTST"></script> <!-- /Added by GoogleAnalytics4 integration --> <link rel="canonical" href="https://oxfordglobal.com/nextgen-biomed/resources/advancing-melanoma-treatment-the-fda-gives-lifileucel-the-greenlight-in-historic-cell-gene-therapy-breakthrough"> <meta property="og:image" content="https://oxfordglobal.com/hubfs/Advancing%20Melanoma%20Treatment%20The%20FDA%20Gives%20Amtgavi%20The%20Greenlight%20in%20Historic%20Cell%20%26%20Gene%20Therapy%20Breakthrough.png"> <meta property="og:image:width" content="1200"> <meta property="og:image:height" content="800"> <meta name="twitter:image" content="https://oxfordglobal.com/hubfs/Advancing%20Melanoma%20Treatment%20The%20FDA%20Gives%20Amtgavi%20The%20Greenlight%20in%20Historic%20Cell%20%26%20Gene%20Therapy%20Breakthrough.png"> <meta property="og:url" content="https://oxfordglobal.com/nextgen-biomed/resources/advancing-melanoma-treatment-the-fda-gives-lifileucel-the-greenlight-in-historic-cell-gene-therapy-breakthrough"> <meta name="twitter:card" content="summary"> <meta http-equiv="content-language" content="en"> <meta name="generator" content="HubSpot"></head> <body class="nextgen-biomed"> <div class="body-wrapper hs-content-id-177607186815 hs-site-page page "> <div data-global-resource-path="git/og-stage/templates/partials/header.html"> <header class="website-header "> <div class="navbar"> <div class="navbar-brands"> <a href="/nextgen-biomed" class="logo-link current-brand"> <img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/NextGen%20Biomed.svg" class="logo-image"> <i class="dropdown fa-solid fa-chevron-down"></i> </a> <div class="brands"> <div class="intro"> <h2> Explore our brands </h2> <div class="desc"> Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. </div> </div> <div class="items"> <div class="item primary-brand"> <a href="/" class="logo-link"><img src="https://oxfordglobal.com/hubfs/logo.jpg" class="logo-image"></a> </div> <div class="item"> <a href="/precision-medicine" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Precision%20Medicine.svg" class="logo-image"></a> </div> <div class="item"> <a href="/discovery-development" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Discovery%20%26%20Development.svg" class="logo-image"></a> </div> <div class="item active-item"> <a href="/nextgen-biomed" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/NextGen%20Biomed.svg" class="logo-image"></a> </div> </div> </div> </div> <div class="flex flex-align-center navbar-nav"> <a href="#" class="navbar-nav-toggle"> <div class="toggle-icons"> <i class="fa-solid fa-bars toggle-open"></i> <i class="fa-solid fa-xmark toggle-close"></i> </div> </a> <ul class="navbar-nav-items"> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Events <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Events.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex-3 divider g-20"> <div class="subnav-item-content bottom-mp-fix"> <h3> In-Person & Online Events </h3> <p>Pivotal moments where high-level industry experts and thought leaders come together for focused knowledge sharing and unparalleled networking opportunities.</p> </div> <div class="subnav-item"> <div class="event-pills"> <a href="/nextgen-biomed/events/nextgen-biomed-2025" class="pill center"> <div class="b">NextGen Biomed 2025</div> <div class="heading-smallcaps"> 12 - 14 Mar 2025 | London, UK </div> </a> <a href="/nextgen-biomed/events/cell-2025" class="pill center"> <div class="b">Cell 2025</div> <div class="heading-smallcaps"> 11-12 Nov 2025 | London, UK </div> </a> </div> </div> </div> <div class="subnav-item flex-2"> <div class="subnav-item-content bottom-mp-fix"> <h3> Online Activities </h3> <p>Our Monthly Science Exchanges and Webinars keep you connected to the conversation.</p> </div> <div class="online-activities-list flex flex-column g-10"> <!-- Individual Online Activity --> <div class="online-activity"> <a href="/nextgen-biomed/online#Process%20Challenges%20in%20ATMP%20Development:%20Overcoming%20Hurdles%20for%20Successful%20Manufacturing" class="cta" target="_blank"> <h3 class="other-resources">01/11/24 - Process Challenges in ATMP Development: Overcoming Hurdles for Successful Manufacturing</h3> </a> </div> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/online" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> All Online Activities</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Community <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Community.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> About </h3> <p>NextGen Biomed is the platform to advance the fields of biologics, vaccines & novel therapeutics approaches, helping to deliver life-saving medicines to patients faster.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/about" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Community </h3> <p>NextGen Biomed is committed to supporting R&D scientists, as well as drug development and manufacturing experts, working with biologics, peptides, and oligonucleotides to overcome complexities at every stage of the drug product lifecycle.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/community" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1 "> <div class="subnav-item-content bottom-mp-fix"> <h3> Media Partners </h3> <p>We work with leading journal publications on reciprocal marketing arrangements.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/media-partners" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Services <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Services.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> In-Person Services </h3> <p>At Oxford Global, our events are designed to connect key life science figures and innovative solution providers, accelerating scientific advancement. Our goal is to create valuable connections and an impactful experience through innovative and collaborative formats.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/in-person-services" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1"> <div class="subnav-item-content bottom-mp-fix"> <h3> Digital Marketing Services </h3> <p>Oxford Global’s products offer a powerful channel to associate your brand with the latest advancements within the industry whilst educating and influencing the industry throughout their buying process.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/digital-marketing-services" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Resources <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Resources.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex-2 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Browse All Resources </h3> <p>The latest in from nextgen biomed research & development</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/resources" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> All NextGen Biomed Resources</a> </div> </div> <div class="subnav-item flex-4 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Latest Resources </h3> <div class="resources"> <div class="resource"> <div class="resource-cover"> <a href="/nextgen-biomed/resources/university-college-london-hospitals-begins-clinical-trial-for-one-off-car-t-treatment-for-lupus" class="resource-cover-link"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/NextGen%20Biomed/University%20College%20London%20Hospitals%20Begins%20Clinical%20Trial%20for%20One-Off%20CAR%20T%20Treatment%20for%20Lupus%201.jpg" class="resource-cover-image"> </a> </div> <div class="resource-content"> <h3 class="resource-heading"> <a href="/nextgen-biomed/resources/university-college-london-hospitals-begins-clinical-trial-for-one-off-car-t-treatment-for-lupus">University College London Hospitals Begins Clinical Trial for One-Off CAR T Treatment for Lupus</a> </h3> <div class="resource-abstract"> <span class="resource-date">08/11/24 - </span> The possibility of a one-off treatment for lupus could offer hope to 69,000 patients in the UK. </div> </div> </div> <div class="top-divider"></div> <div class="resource"> <div class="other-resources"><a href="/nextgen-biomed/resources/clesrovimab-shows-positive-results-as-preventative-treatment-for-rsv-in-pre-term-and-full-term-infants">07/11/24 - Clesrovimab Shows Positive Results as Preventative Treatment for RSV in Pre-Term and Full-Term Infants</a></div> </div> <div class="top-divider"></div> <div class="resource"> <div class="other-resources"><a href="/nextgen-biomed/resources/the-nist-awards-1-5-million-to-improve-standardisation-in-regenerative-medicine">31/10/24 - The NIST Awards $1.5 Million to Improve Standardisation in Regenerative Medicine</a></div> </div> </div> </div> </div> <div class="subnav-item flex-3"> <div class="subnav-item-content bottom-mp-fix"> <h3> Featured Resource </h3> <div class="resources flex flex-column g-5"> <a href="https://oxfordglobal.com/nextgen-biomed/resources/sponsored/webinar/wuxibiologics/sp-webinar-optimizing-bispecific-antibody-production-from-identifying-optimal-pairings-to-scale-up-processes"> <div class="sponsor-resource flex-column"> <div class="resource-cover img-fluid"> <div class="sponsor-resource-cover-link"> <img src="https://oxfordglobal.com/hubfs/Digital%20Marketing/Webinars/Email%20and%20Social%20Collateral/NGB%20-%20Wuxi%20Biologics/WuXi%20Biologics.png" class="sponsor-resource-cover-image"> </div> </div> <div class="resource-content p-15"> <h3 class="resource-heading"> Optimizing Bispecific Antibody Production: From Identifying Optimal Pairings to Scale-up Processes </h3> <div class="resource-abstract"> On-demand webinar presented by Dr Jiansheng Wu, Head of Protein Sciences and Vice President at WuXi Biologics </div> </div> </div> </a> </div> </div> </div> </div> </div> </li> <li class="navbar-nav-item show-sm hide-md hide-lg hide-xl"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});" class="navbar-nav-item-link">Contact</a> </li> <li class="navbar-nav-item show-sm hide-md hide-lg hide-xl"> <a href="#" class="navbar-nav-item-link">Our Brands <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-items"> <h2> Explore our brands </h2> <div class="desc"> Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/">Oxford Global</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/precision-medicine">Precision Medicine</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/discovery-development">Discovery & Development</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/nextgen-biomed">NextGen Biomed</a> </div> </div> </div> </div> </li> </ul> </div> <div class="flex flex-align-center hide-sm show-md show-lg show-xl"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});" class="navbar-button">Contact</a> </div> </div> </header></div> <main id="main-content"> <div class="resource-single"> <div class="header bg-primary-light"> <div class="container-wrapper"> <div class="wide-container header-container"> <div class="header-content flex-1"> <div class="heading-smallcaps"> Industry Spotlights & Insight Articles </div> <h1 class="heading"> Advancing Melanoma Treatment: The FDA Gives Lifileucel The Greenlight in Historic Cell & Gene Therapy Breakthrough </h1> <div class="byline"> Edited by Lucia Simmen | 06 March 2024 </div> <div class="abstract"> The Food and Drug Administration (FDA) approved lifileucel, a one-of-a-kind T-cell therapy developed by Iovance Biotherapeutics for treating melanoma. </div> </div> <div class="header-graphic flex-1"> <img src="https://oxfordglobal.com/hubfs/Advancing%20Melanoma%20Treatment%20The%20FDA%20Gives%20Amtgavi%20The%20Greenlight%20in%20Historic%20Cell%20%26%20Gene%20Therapy%20Breakthrough.png" class="header-graphic-image"> </div> </div> </div> </div> <div class="container-wrapper"> <div class="wide-container"> <div class="content"> <div class="content-body text-gap"> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; padding-left: 0cm; text-align: left;"><strong>Introduction</strong></p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; padding-left: 0cm; text-align: left;"> </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; padding-left: 0cm; text-align: left;">The FDA approved its first-ever <a href="https://oxfordglobal.com/cell/resources/cell-therapy-for-solid-tumors" rel="noopener" target="_blank">cell therapy for solid tumours</a>. Lifileucel (AMTGAVI) is a specific type of T-cell therapy called tumour-infiltrating lymphocyte (TIL) therapy, developed by Iovance Biotherapeutics.</p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; padding-left: 0cm; text-align: left;"> </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; padding-left: 0cm; text-align: left;">This marked a turning point in the <a href="https://oxfordglobal.com/cell/events/cell-gene-2024" rel="noopener" target="_blank">cell and gene therapy (CGT) field </a> because it is the first and only time an individualised T-cell therapy has received accelerated FDA approval for a solid tumour. This tumour-derived autologous T-cell immunotherapy is used to treat melanoma. </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; padding-left: 0cm; text-align: left;"> </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; padding-left: 0cm; text-align: left;">In the USA there are currently 100,000 people living with melanoma, <a href="https://www.cancer.org/cancer/types/melanoma-skin-cancer/about/key-statistics.html#:~:text=Melanoma%20accounts%20for%20only%20about,majority%20of%20skin%20cancer%20deaths" rel="noopener" target="_blank"><span style="color: #4a6ee0;">while melanoma only accounts for 1% of skin cancers it is responsible for a large majority of skin cancer deaths</span></a>. Furthermore, according to the <a href="https://www.skincancer.org/skin-cancer-information/skin-cancer-facts/" rel="noopener" target="_blank"><span style="color: #4a6ee0;">Skin Cancer Foundation</span></a>, it is estimated that the number of new melanoma cases diagnosed in 2024 will increase by 7.3%. This demonstrates the growing necessity to develop CGTs to treat this life-threatening disease.</p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; padding-left: 0cm; text-align: left;"> </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; padding-left: 0cm; text-align: left;"><strong>Manufacturing and Development </strong></p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; padding-left: 0cm; text-align: left;"> </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; padding-left: 0cm; text-align: left;">Lifileucel is a tumour-derived autologous T cell immunotherapy. It separates T cells from a small section of the patient’s tumour tissue. Those cells are then cultured, expanded, and reinfused into the same patient as a single dose for infusion. <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-treat-patients-unresectable-or-metastatic-melanoma" rel="noopener" target="_blank"> Lifileucel effectively replenishes the body with these anti-cancer immune cells</a>, compensating for the reduced efficacy of naturally occurring TILs over time.</p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; padding-left: 0cm; text-align: left;"> </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; padding-left: 0cm; text-align: left;"><strong>Related: </strong></p> <ul style="text-align: left;"> <li style="text-align: justify;"><span style="color: windowtext;"><a href="https://oxfordglobal.com/cell/resources/comparing-allogeneic-and-autologous-stem-cell-transplantation-approaches" rel="noopener" target="_blank"><span style="color: #4a6ee0;">Comparing Allogeneic and Autologous Stem Cell Transplantation Approaches</span></a></span></li> <li style="text-align: justify;"><span style="color: windowtext;"><a href="https://oxfordglobal.com/cell/resources/applications-of-stem-cells-in-personalised-medicine" rel="noopener" target="_blank"><span style="color: #4a6ee0;">Applications of Stem Cells in Personalised Medicine</span></a></span></li> <li style="text-align: justify;"><span style="color: windowtext;"><a href="https://oxfordglobal.com/cell/resources/in-conversation-with-sophie-mountcastle-network-manager-innovation-hubs-for-gene-therapies" rel="noopener" target="_blank"><span style="color: #4a6ee0;">In Conversation With… Sophie Mountcastle, Network Manager, Innovation Hubs for Gene Therapies</span></a></span> </li> </ul> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; padding-left: 18pt; text-align: left;"> </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; padding-left: 0cm; text-align: left;"><strong>Clinical Trial Results</strong></p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; padding-left: 0cm; text-align: left;"> </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; padding-left: 0cm; text-align: left;">FDA approval was based on the safety and efficacy <a href="https://www.sec.gov/Archives/edgar/data/1425205/000110465924025082/tm246580d1_ex99-1.htm" rel="noopener" target="_blank"><span style="color: #4a6ee0;">results from the global C-144-01 clinical trial</span></a>. This trial comprised a sample of 89 patients with unresectable (unable to be removed with surgery) or metastatic melanoma (cancer that has spread from its site of origin to other parts of the body) who had already been treated with at least one systemic therapy. </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; padding-left: 0cm; text-align: left;"> </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; padding-left: 0cm; text-align: left;">Among the 73 patients treated at the recommended dose, the objective response rate was 31.5%, with 4.1% experiencing a complete response and 27.4% a partial response. Additionally, a significant proportion of responders—56.5%, 47.8%, and 43.5%—maintained their responses without tumour progression or mortality at six, nine, and 12 months, respectively.</p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; padding-left: 0cm; text-align: left;"> </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; padding-left: 0cm; text-align: left;">The accelerated approval of lifileucel marked a milestone in Iovance’s mission to develop the next generation of cell and gene therapies. Frederick Vogt, CEO and President of Iovance Biotherapeutics, proudly stated: “Given the unmet needs in the advanced melanoma community, we are proud to offer a personalised, one-time therapeutic option for these patients.”</p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; padding-left: 0cm; text-align: left;"> </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; padding-left: 0cm; text-align: left;"><strong>Challenges and Limitations</strong></p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; padding-left: 0cm; text-align: left;"> </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; padding-left: 0cm; text-align: left;">Manufacturing CGTs has always presented unique challenges that are not present when developing more traditional therapies and lifileucel was no different. While lifileucel's approval was a major step forward, some obstacles still need to be overcome. </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; padding-left: 0cm; text-align: left;"> </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; padding-left: 0cm; text-align: left;">The therapy <a href="https://ir.iovance.com/news-releases/news-release-details/iovances-amtagvitm-lifileucel-receives-us-fda-accelerated" rel="noopener" target="_blank"><span style="color: #4a6ee0;">carries a boxed warning for adverse side effects </span></a>associated with the treatment, as a result, <a href="https://www.fiercepharma.com/pharma/fda-approves-iovances-amtagvi-first-cell-therapy-solid-tumor" rel="noopener" target="_blank"><span style="color: #4a6ee0;">the drug is only offered at assigned treatment centres in an inpatient hospital setting.</span></a> Furthermore patients must stay within a 2-hour radius of the treatment facility for several weeks after receiving the infusion to monitor for any severe side effects.</p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; padding-left: 0cm; text-align: left;"> </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; padding-left: 0cm; text-align: left;">In terms of patient eligibility, patients who cannot undergo surgery or those without sufficient resected tumour tissues will not be suitable subjects for the therapy. Therefore, this vastly reduces the number of patients living with melanoma who meet the patient eligibility criteria.</p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; padding-left: 0cm; text-align: left;"> </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; padding-left: 0cm; text-align: left;">For autologous therapies such as lifileucel, there is no straightforward approach for scale-up because each batch of cells is manufactured for an individual patient. Each unique collection of cells varies in starting material and yield, which highlights the importance of developing innovative solutions to increase throughput and efficiency.</p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; padding-left: 0cm; text-align: left;"> </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; padding-left: 0cm; text-align: left;"><strong>Conclusion</strong></p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; padding-left: 0cm; text-align: left;"> </p> <p style="margin-top: 0cm; margin-right: 0cm; margin-bottom: 0cm; padding-left: 0cm; text-align: left;">This momentous achievement represents a highly important step towards achieving accessible and commercially viable CGTs. However, there is room for improvement regarding making the manufacturing process more efficient and scalable. Additionally, patient eligibility criteria, including the requirement for sufficient resected tumour tissues, restrict the therapy's applicability to a wider population of melanoma patients. Overall, lifileucel underscores the transformative potential of personalised therapies in treating melanoma. </p> <div class="content-body-footer"> </div> </div> <div class="content-sidebar"> <div class="related-articles"> <h3 class="center">Related Resources</h3> <div class="article"> <a href="/nextgen-biomed/resources/cell-therapy-for-solid-tumors"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Cell%20and%20Gene/Cell%20Therapy%20For%20Solid%20Tumors.jpg" class="cover-graphic-image"> </div> </a><div class="content"><a href="/nextgen-biomed/resources/cell-therapy-for-solid-tumors"> <h4> Cell Therapy for Solid Tumors: An Innovative Approach to Cancer Treatment </h4> <div class="abstract"> Cell therapy for solid tumours is an innovative cancer treatment that uses a patient's own immune cells or donor cells to fight cancer, but its effectiveness varies by tumour type and patient's immune system. Although it offers new hope, it poses risks such as cytokine release syndrome and neurotoxicity. Recent advancements have led to better targeting, combination therapies, and next-generation treatments, with future research aimed at improving safety, effectiveness, and accessibility, potentially revolutionising cancer care. </div> <div class="read-more"> <a href="/nextgen-biomed/resources/cell-therapy-for-solid-tumors" class="read-more-link">Read More</a> </div></a> </div> </div> <div class="article"> <a href="/nextgen-biomed/resources/interview-with-lindsay-davies"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Cell%20and%20Gene/MicrosoftTeams-image%20(4).png" class="cover-graphic-image"> </div> </a><div class="content"><a href="/nextgen-biomed/resources/interview-with-lindsay-davies"> <h4> Spotlight On: Lindsay Davies, Chief Scientific Officer of NextCell Pharma </h4> <div class="abstract"> We caught up with Lindsay Davies, Chief Scientific Officer of NextCell Pharma, to hear about to hear about the latest advancements in stromal cell therapy in anticipation of her presentation at our Cell & Gene 2024 Congress this November. </div> <div class="read-more"> <a href="/nextgen-biomed/resources/interview-with-lindsay-davies" class="read-more-link">Read More</a> </div></a> </div> </div> </div> <div class="related-online-activities"> <h3 class="center">Related Online Activities</h3> Join the conversation with our upcoming Monthly Science Exchanges and Webinars: <div class="online-activity"> <div class="heading-smallcaps"> 01/11/24 </div> <a href="/nextgen-biomed/online#Process%20Challenges%20in%20ATMP%20Development:%20Overcoming%20Hurdles%20for%20Successful%20Manufacturing">Process Challenges in ATMP Development: Overcoming Hurdles for Successful Manufacturing</a> </div> </div> </div> </div> </div> </div> </div> <div class="newsletter-cta"> <h2 class="heading">Subscribe to our newsletter</h2> <div class="message"> Sign up for our monthly Newsletter to keep up with all things NextGen Biomed </div> <div class="button-wrapper"> <a href="#" class="button hs-cta-trigger-button hs-cta-trigger-button-177053686099">Newsletter Sign-Up</a> </div> </div> </main> <div data-global-resource-path="git/og-stage/templates/partials/footer.html"><footer class="website-footer flex flex-column g-20"> <div class="footer-columns"> <div class="footer-column"> <a href="https://oxfordglobal.com" class="site-logo-link"> <img src="https://oxfordglobal.com/wp-content/uploads/2023/03/Oxford-Global-Logo-Stacked-Websize.png" class="site-logo"> </a> </div> <div class="footer-column"> <h3>Brands</h3> <ul> <li> <a href="/precision-medicine/">Precision Medicine</a> </li> <li> <a href="/discovery-development/">Discovery & Development</a> </li> <li> <a href="/nextgen-biomed/">NextGen Biomed</a> </li> </ul> </div> <div class="footer-column"> <h3>Services</h3> <ul> <li> <a href="https://oxfordglobal.com/in-person-services/"> In-Person Services </a> </li> <li> <a href="https://oxfordglobal.com/digital-marketing-services/"> Digital Marketing Services </a> </li> </ul> <h3>Upcoming Events</h3> <ul> <li> <a href="https://oxfordglobal.com/calendar/"> Event Calendar </a> </li> </ul> </div> <div class="footer-column"> <h3>Company</h3> <ul> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/about-us/"> About </a> </li> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/vacancies/"> Vacancies </a> </li> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/csr-policy/"> CSR Policy </a> </li> <li class="elementor-icon-list-item"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});"> Contact </a> </li> </ul> </div> <div class="footer-column"> <p> <a href="tel:+441865248455">+44 1865 248 455</a><br> <a href="mailto:help@oxfordglobal.com">help@oxfordglobal.com</a> </p> <p> <strong>Our UK Address:</strong><br> Godstow Court<br> Minns Business Park<br> Botley<br> Oxford, OX2 0JB </p> <p> <strong>Our US Address:</strong><br> 100 Cambridge Street<br> 14th Floor<br> Boston<br> MA 02114 </p> </div> </div> <div class="footer-bottom grid g-20"> <div class="span8 span12-sm span12-md flex flex-column g-10"> <div class="copyright"> © Oxford Global Marketing Ltd. All rights reserved. </div> <ul class="legal-links flex flex-row g-30 flex-column-sm g-sm-10"> <li><a href="https://oxfordglobal.com/legal/">Terms & Conditions</a></li> <li><a href="https://oxfordglobal.com/legal/privacy-policy/">Privacy Policy</a></li> <li><a href="https://oxfordglobal.com/legal/website-terms/">Cookies</a></li> <li><a href="https://www.wishagency.co.uk/" target="_BLANK">Digital Agency Wish</a></li> </ul> </div> <div class="span4 span12-sm span12-md flex-align-end"> <ul class="social-links flex flex-row flex-justify-end flex-justify-center-sm flex-justify-center-md g-30"> <li><a href="https://www.facebook.com/OGConferences/" target="_BLANK"><i class="fa-brands fa-square-facebook"></i></a></li> <li><a href="https://www.linkedin.com/company/oxford-global/" target="_BLANK"><i class="fa-brands fa-linkedin"></i></a></li> <li><a href="https://twitter.com/OGConferences" target="_BLANK"><i class="fa-brands fa-square-x-twitter"></i></a></li> </ul> </div> </div> </footer></div> </div> <script src="/hs/hsstatic/jquery-libs/static-1.1/jquery/jquery-1.7.1.js"></script> <script>hsjQuery = window['jQuery'];</script> <!-- HubSpot performance collection script --> <script defer src="/hs/hsstatic/content-cwv-embed/static-1.1293/embed.js"></script> <script src="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/182600797781/1731148644227/git/og-stage/js/inlineSVG.min.js"></script> <script src="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/135724366742/1725380923802/git/og-stage/js/main.min.js"></script> <script> function getVideoId(url) { var regExp = /^.*(youtu.be\/|v\/|u\/\w\/|embed\/|watch\?v=|\&v=)([^#\&\?]*).*/; var match = url.match(regExp); if (match && match[2].length == 11) { return match[2]; } else { return false; } } function getVideoEmbed(id) { return '<iframe src="https://www.youtube.com/embed/' + id + '" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" allowfullscreen style="aspect-ratio: 16 / 9; width: 100%;"></iframe>'; } jQuery("div.content-body .wp-block-embed__wrapper:contains('youtu')").each(function() { var yt_url = $(this).html().trim(); var yt_id = getVideoId(yt_url); var yt_embed = getVideoEmbed(yt_id); $(this).html(yt_embed); }); </script> <!-- Start of HubSpot Analytics Code --> <script type="text/javascript"> var _hsq = _hsq || []; _hsq.push(["setContentType", "standard-page"]); _hsq.push(["setCanonicalUrl", "https:\/\/oxfordglobal.com\/nextgen-biomed\/resources\/advancing-melanoma-treatment-the-fda-gives-lifileucel-the-greenlight-in-historic-cell-gene-therapy-breakthrough"]); _hsq.push(["setPageId", "hubdb-177607186815-30817717-181072999864"]); _hsq.push(["setContentMetadata", { "contentPageId": "hubdb-177607186815-30817717-181072999864", "legacyPageId": "hubdb-177607186815-30817717-181072999864", "contentFolderId": null, "contentGroupId": null, "abTestId": null, "languageVariantId": 177607186815, "languageCode": "en", }]); </script> <script type="text/javascript" id="hs-script-loader" async defer src="/hs/scriptloader/8696823.js"></script> <!-- End of HubSpot Analytics Code --> <script type="text/javascript"> var hsVars = { render_id: "0cd82d95-28c6-4973-84af-139b642e0077", ticks: 1732699692304, page_id: 177607186815, dynamic_page_id: "hubdb-177607186815-30817717-181072999864", content_group_id: 0, portal_id: 8696823, app_hs_base_url: "https://app.hubspot.com", cp_hs_base_url: "https://cp.hubspot.com", language: "en", analytics_page_type: "standard-page", scp_content_type: "", analytics_page_id: "hubdb-177607186815-30817717-181072999864", category_id: 1, folder_id: 0, is_hubspot_user: false } </script> <script defer src="/hs/hsstatic/HubspotToolsMenu/static-1.354/js/index.js"></script> </body></html>